Company R&G PharmaStudies Co., Ltd.

Equities

301333

CNE100005K44

Healthcare Facilities & Services

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Other Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
45 ^CNY	-0.13%		-7.99%	-30.21%

Apr. 21	R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

R&G PharmaStudies Co Ltd is a China-based company mainly engaged in the provision of professional clinical trial outsourcing services. The Company's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The Company operates its businesses primarily in the domestic market.

Number of employees: 2,042

CNY in Million	2022	Weight	2023	Weight	Delta
Clinical Trial Operation 49.1 %	300	47.0 %	354	49.1 %	+18.32%
Clinical Trial Site Management 25.8 %	154	24.2 %	186	25.8 %	+20.58%
Data Management and Statistical Analysis 11.0 %	73	11.4 %	80	11.0 %	+9.87%
Biological Sample Testing 5.1 %	45	7.0 %	36	5.1 %	-18.61%
Clinical Pharmacology 5.0 %	32	5.0 %	36	5.0 %	+12.39%
Clinical Trial Consulting 4.0 %	34	5.4 %	29	4.0 %	-16.12%

CNY in Million	2022	Weight	2023	Weight	Delta
China 93.5 %	605	94.9 %	674	93.5 %	+11.47%
Overseas 6.5 %	32	5.1 %	47	6.5 %	+44.57%

Managers	Title	Age	Since
Jie Wu CEO	Chief Executive Officer	63	08-08-21
Shu Qi Li FOU	Founder	59	08-08-21
Qian Zhao DFI	Director of Finance/CFO	40	14-01-31
Hong Guan CHM	Chairman	47	10-03-31
Yan Zheng CTO	Chief Tech/Sci/R&D Officer	40	09-06-30
Wei Guo Zhang CTO	Chief Tech/Sci/R&D Officer	55	14-03-31
Wei Wang BRD	Director/Board Member	46	08-07-31
Le Yan Teng BRD	Director/Board Member	52	09-09-30
Gang Chen PRN	Corporate Officer/Principal	68	16-06-30

Members of the board	Title	Age	Since
Le Yan Teng BRD	Director/Board Member	52	09-09-30
Shu Qi Li FOU	Founder	59	08-08-21
Hong Bei Zheng BRD	Director/Board Member	58	14-12-31
Jie Wu CEO	Chief Executive Officer	63	08-08-21
Wei Wang BRD	Director/Board Member	46	08-07-31
Qian Chen BRD	Director/Board Member	63	15-12-31
Hong Li BRD	Director/Board Member	55	15-08-31
Lu Yang BRD	Director/Board Member	42	15-08-31
Hong Guan CHM	Chairman	47	10-03-31
Wei Guo Zhang CTO	Chief Tech/Sci/R&D Officer	55	14-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	96,000,000	30,192,000 ( 31.45 %)	0	31.45 %

Name	Equities	%	Valuation
GF Fund Management Co., Ltd. 11.54 %	2,770,200	11.54 %	19 M ¥
Zhong Ou Asset Management Co., Ltd 7.930 %	1,903,128	7.930 %	13 M ¥
Aegon-Industrial Fund Management Co., Ltd. 3.082 %	739,657	3.082 %	5 M ¥
Baoying Fund Management Co., Ltd. 2.810 %	674,342	2.810 %	5 M ¥
Everbright PGIM Fund Management Co. Ltd. 0.6469 %	155,260	0.6469 %	1 M ¥
Golden Trust Sinopac Fund Management Co., Ltd. 0.5827 %	139,840	0.5827 %	934 263 ¥
China Asset Management Co., Ltd. 0.4525 %	108,597	0.4525 %	725 530 ¥
AXA-SPDB Investment Managers Co., Ltd. 0.4400 %	105,600	0.4400 %	705 507 ¥
Beixin Ruifeng Fund Management Co., Ltd. 0.3125 %	75,000	0.3125 %	501 071 ¥
CIB Fund Management Co., Ltd. 0.2240 %	53,760	0.2240 %	359 167 ¥

Name	Equities	%	Valuation
Jie Wu 38.24 %	27,532,800	38.24 %	184 M ¥
Hong Bei Zheng 16.30 %	11,736,000	16.30 %	78 M ¥

R&G PharmaStudies Co., Ltd.

North Tower, Huatong Building 19 Chegongzhuang West Road

100048, Beijing

http://www.rg-pharma.com

address R&G PharmaStudies Co., Ltd.(301333)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45 CNY

Average target price

60.5 CNY

Spread / Average Target

+34.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Other Healthcare Facilities & Services

	1st Jan change	Capi.
R&G PHARMASTUDIES CO., LTD.	-30.21%	598M
HCA HEALTHCARE, INC.	+18.41%	83.07B
CVS HEALTH CORPORATION	-29.08%	70.89B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.59%	28.32B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.08%	17.73B
FRESENIUS SE & CO. KGAA	+2.07%	17.43B
QUEST DIAGNOSTICS INCORPORATED	+0.93%	15.64B
REDE D'OR SÃO LUIZ S.A.	+6.78%	13.46B
FRESENIUS MEDICAL CARE AG	+8.40%	12.82B
NATERA, INC.	+68.45%	12.69B

Other Healthcare Facilities & Services